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p53HPV16 E6 deregulates G1/S cell cycle progression through p53 degradation preventing transcription of the
CDK inhibitor p21WAF1. However, additional mechanisms independent of p53 inactivation appear to exist.
Here, we report that HPV16 E6 targets the cellular factor p150Sal2, which positively regulates p21WAF1
transcription. HPV16 E6 associates with p150Sal2, inducing its functional inhibition by preventing its binding
to cis elements on the p21WAF1 promoter. A HPV16 E6 mutant, L110Q, which was unable to bind p150Sal2, did
not affect the ability of the cellular protein to bind p21WAF1 promoter, underlining the linkage between these
events. These data describe a novel mechanism by which HPV16 E6 induces cell cycle deregulation with a
p53-independent pathway. The viral oncoprotein targets p150Sal2, a positive transcription regulator of
p21WAF1 gene, preventing G1/S arrest and allowing cellular proliferation and efﬁcient viral DNA replication.Biology Group, International
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Epidemiological and biological studies have clearly demonstrated
that approximately 15 mucosal human papillomaviruses (HPVs),
referred to as high-risk HPV types, are the etiological agents of cervical
cancer (zur Hausen, 2000). Among these, HPV16 is the most frequent
type associated to cervical cancer worldwide (Clifford et al., 2003).
The products of two early genes, E6 and E7, act as major oncoproteins
in HPV-induced carcinogenesis (Munger et al., 2004). Since the viral
DNA replication is totally dependent on host cellular machinery, these
oncoproteins have developed a number of mechanisms to drive cells
into S phase (Munger et al., 2004). In a normal situation, the exposure
of quiescent cells to mitogens gives rise to activation of cyclin/cyclin
dependent kinase (CDK) complexes, with concomitant dissociation
and/or degradation of CDK inhibitors, such as p21WAF1, a key regulator
of the G1/S transition (Ekholm and Reed, 2000; Kaldis and Aleem,
2005). The transcription of p21WAF1 gene is known to be regulated by
several cellular factors, including the tumor suppressor protein p53(el-Deiry et al., 1993). Upon DNA damage, accumulation of p53 leads
to increased p21WAF1 levels, inducing a G1 arrest and allowing DNA
reparation before replication (Sherr and McCormick, 2002). Further-
more, it has been shown that p21WAF1 can bind to PCNA (prolifer-
ating-cell nuclear antigen), an essential DNA replication factor, and
this binding is sufﬁcient for the inhibition of DNA replication based on
simian virus 40 (Chen et al., 1995).
HPV16 E6 mediates the interaction between the ubiquitin protein
ligase E6AP and p53, promoting degradation of the latter via the
proteasome pathway (Kao et al., 2000). Thus, HPV16 E6 expressing
cells in presence of DNA damages do not accumulate p21WAF1 and
continue to proliferate (Mantovani and Banks, 2001). We have
previously presented several lines of evidence that E6 protein has
an additional p53-independent mechanism to down-regulate
p21WAF1 expression and promote cell cycle progression. In fact, E6
from the benign cutaneous HPV1 and a HPV16 E6 mutant that are
unable to target p53 for degradation, were still competent to inhibit
p21WAF1 transcription and induce cellular proliferation (Malanchi et
al., 2004, 2002). However, this E6 p53-independent mechanism still
remains to be elucidated.
Few reports describe that the product of Sal2 gene, p150Sal2, acts in
part as a p53-independent positive regulator of p21WAF1 transcription
(Li et al., 2004). Interestingly, p150Sal2 (Li et al., 2001) has been found
to be targeted by the oncoprotein large T antigen from the mouse
polyomavirus.
Here, we show that HPV16 E6 is able to bind to and inactivate the
transcriptional functions of p150Sal2 in several experimental models.
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HPV16 E6 inhibits p21WAF1 transcription in the absence of p53
We have previously observed that HPV16 is able to alter the
regulation of the restriction point in the G1 phase of the cell cycle by
down-regulation of p21WAF1 expression by a mechanism that is
independent of p53 inactivation (Malanchi et al., 2004, 2002). To
investigate whether this E6 p53-independent mechanism affects
p21WAF1 mRNA transcription, the activity of the p21WAF1 promoter
linked to a luciferase reporter gene was evaluated in primary human
ﬁbroblast (POF) in the presence of a siRNA targeting p53 or a scramble
control. We observed that the activity of the p21WAF1 promoter
declined with increasing concentrations of HPV16 E6 wild type in
presence and absence of p53 (Figs. 1A and B). In addition, HPV16 E6
was able to inhibit p21WAF1 promoter in a human osteosarcoma cell
line (SaOS-2) that is p53 null (Fig. 1C).n
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Fig. 1. HPV16 E6 inhibits p21WAF1 transcription in the absence of p53. (A) Determination of
(B) Luciferase assays were performed using increasing concentrations of pLXSN-HPV16 E6
stably expressing scramble shRNA or p53 shRNA. Luciferase activities were expressed as fold
experiments; SEM is indicated by the error bars. (C) Luciferase assays were performed using
luciferase construct in SaOS-2 cells (p53-null). Luciferase activities are expressed as relative
performed as described in the legend of B. Results are from at least three independent experim
5′ end deletions of p21WAF1 promoter with the two p53 and p150Sal2 binding sites (left pa
empty vector or HPV16 E6 wild type and the p21WAF1 promoter–reporter constructs. The dWe next analyzed the ability of two HPV16 E6 mutants, L110Q and
G130V, to modulate p21. It has been previously reported that both
mutants are unable to bind E6AP and induce p53 degradation (Liu et
al., 1999). The mutation G130V was still able to inhibit the p21
promoter in a dose dependent-manner, whereas the mutation L110Q
totally abolished the suppression of the p21WAF1 promoter by HPV16
E6 (Fig. 1B).
Besides p53, another cellular protein, p150Sal2, positively regulates
p21WAF1 expression (Li et al., 2004). Therefore, we next determined
whether p150Sal2 could also be involved in the HPV16 E6-mediated
inhibition of p21WAF1 transcription. To do this, several different
deletion constructs of the p21WAF1 promoter were analyzed in
transient transfection experiments in human osteosarcoma cell line
(SaOS-2) (Fig. 1C). These data showed that after complete deletion of
the two p150Sal2 cis elements, p21WAF1 transcription is no longer
down-regulated by HPV16 E6, suggesting the possibility that the viral
oncoprotein targets p150Sal2.5 0.50 0.75 1.00 1.25
+empty vector
+HPV16 E6
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p53 levels in POFs stably expressing scramble shRNA or shRNAp53 by immunoblotting.
wild type co-transfected with 1 μg of p21WAF1 promoter-luciferase construct in POFs
induction compared to empty pLXSN vector. Results are from at least three independent
increasing concentrations of HPV16 E6 co-transfected with 1 μg of p21WAF1 promoter-
luciferase unit (RLU) measuring p21WAF1 promoter activity. (D) Luciferase assays were
ents; SEM is indicated by the error bars. (E) Schematic representation of full length and
nel). CAT assays were performed with extracts from SaOS-2 cells transfected with the
ata are the means of three independent experiments (right panel).
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afﬁnity for p150Sal2
We next determined whether the down-regulation of p21WAF1
promoter activity in absence of p53 by HPV16 E6 could be due to its
ability to associate with p150Sal2. We ﬁrst performed immunopre-
cipitation experiments. HPV16 E6 fused with hemagglutinin (HA) at
the C terminal (HPV16 E6HA) was stably expressed in SaOS-2 cells,
which were subsequently transfected with a plasmid expressing
Flag-p150Sal2 fusion protein. As shown in Fig. 2A, an anti HA
antibody efﬁciently immunoprecipitated p150Sal2 protein in HPV16
E6-HA SaOS-2 cells transfected with p150-Flag, but not in the mock
cells. Also an anti-Flag antibody efﬁciently immunoprecipitated
HPV16 E6 protein (Fig. 2B), providing an additional evidence that
the two proteins can interact. Based on the fact that HPV16 E6
G130V mutant is still able to inhibit p21WAF1 expression in a p53-
independent mechanism, we hypothesized that this mutant has also
retained the ability to interact with p150Sal2, while this property
should not be shared with the HPV16 E6 L110Q mutant. To conﬁrm
this hypothesis, we next analyzed the ability of the two HPV16 E6
mutants, L110Q and G130V, to bind p150Sal2 in a GST-pull down
assay. The L110Q mutation completely abolished the binding to
p150Sal2 (Fig. 2C), while G130V was still able to interact with
p150Sal2, although with reduced efﬁciency in respect to the HPV16
E6 wild-type protein (Fig. 2C).
Next we compared the ability of HPV16 E6 wild type and
mutants (L110Q and G130V) to down-regulate the expression of the
endogenous p21WAF1 gene. POFs were transduced with recombinant
retroviruses expressing wild type, L110Q or G130V HPV16 E6
(Fig. 3A) and the endogenous mRNA levels of p21WAF1were
determined in all cell lines by quantitative RT-PCR (Fig. 3B). The
wild type HPV16 E6 protein, as expected, strongly repressed
p21WAF1 transcription. HPV16 E6 G130V was still able to down-
regulate p21WAF1 mRNA, although with less efﬁciency than the wild
type protein. L110Q mutant was even less efﬁcient than G130V in
blocking p21WAF1 transcription, although it appeared to retain aA
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Fig. 2. HPV16 E6 targets and inhibits p150Sal2. (A–B) SaOS-2 cells were transduced with retro
protein (pLXSN-HPV16 HA-E6) and then transfected with plasmids expressing pcDNA-p150
antibody (A) or an anti Flag antibody (B). The input represents 10% of the protein extract us
(C) HPV16 E6 wild type, G130V and L110Q proteins were expressed as a GST fusion in B
recombinant proteins were incubated with POF extracts. Beads were washed and captured pr
anti-GST antibodies. The input represents 10% of the protein extract used for incubation.weak inhibitory activity (Fig. 3B). Accordingly, the proliferative
status of the cell lines expressing the different HPV16 E6 proteins
correlated with their efﬁciency in binding p150Sal2 and down-
regulating p21WAF1 expression (Figs. 3C and D).
HPV16 E6 induces the accumulation of a transcriptional inactive
p150Sal2 form
Several independent studies reported that the interaction of E6
protein with cellular factors often results in their rapid degradation
(Mantovani and Banks, 2001). Therefore, we next determined
whether HPV16 E6 decreases the intracellular levels of p150Sal2 in
POFs. Unexpectedly, p150Sal2 levels were clearly elevated in POFs
transduced with the HPV16 E6 wild-type retrovirus (Fig. 4A). This
accumulation was less evident or completely undetectable in cells
expressing the HPV16 E6 G130V or L110Q mutant, respectively
(Fig. 4A). HPV16 E6 induced p150Sal2 accumulation also in the p53-
null SaOS-2 cells (Fig. 4B), demonstrating that the stabilization of
p150Sal2 is not a consequence of the E6-mediated p53 inactivation. In
addition, the HPV16 E6-mediated p150Sal2 accumulation was
detected in HPV-positive cervical cancer-derived cell lines SiHa
(HPV16), CaSki (HPV16) and HeLa (HPV18), but not in the cervical
cancer line C33A that is HPV-negative (Fig. 4C). Gene silencing of
HPV16 E6 and E7 expression in CaSki cells resulted in a strong
reduction of p150Sal2 levels (Fig. 4D). Importantly, we observed that
p150Sal2 accumulation always correlated with the down-regulation of
p21WAF1 levels in POFs, SaOS-2 and cervical-cancer derived cells
(SiHa, CaSki and HeLa) (Figs. 4B–D), suggesting that the stabilized
form of p150Sal2 is inactive. To conﬁrm this hypothesis, we
investigated whether the oncoprotein could affect the ability of
p150Sal2 to bind the p21WAF1 promoter by chromatin immunoprecip-
itation (ChIP). Based on the predicted p150Sal2 binding sites on the
p21WAF1 promoter (Li et al., 2001) and Fig. 1E, primers were designed
outside this region. Cellular extracts of SaOS-2 cells transduced with
empty (pLXSN) or HPV16 E6 wild type or mutant retrovirus were
immunoprecipitated using an anti-p150Sal2 antibody. As shown inB IB HA
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viral empty vector (pLXSN) or recombinant retrovirus expressing HPV16 E6-HA fusion
-Flag or pcDNA-Flag. The cell lysates were immuno-precipitated (IP) using an anti-HA
ed for incubation. HA and Flag-tagged proteins were detected by immunoblotting (IB).
L21 E. coli strain puriﬁed and immobilized on Glutathione-sepharose beads. Puriﬁed
oteins were analyzed by SDS-PAGE (12% gel) and immunoblotting with anti-p150Sal2 or
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Fig. 3. Abilities of theHPV16 E6mutants to down-regulate p21WAF1 and to induce cellular proliferation. (A) ThemRNA levels of infectedHPV16 E6wild-type,HPV16 E6G130V andHPV16
E6 L110Qwere controlled in POF infected cells by quantitative RT-PCR. (B) p21WAF1 mRNA levels were quantiﬁed by real-time RT-PCR in POF expressing HPV16 E6wild-type ormutants.
Quantiﬁcation was normalized with respect to two different control mRNAs, β-actin and glyceraldehyde-3-phosphate dehydrogenase (GAPDH). The data are the means of three
experiments performed with three independent RNA extractions and RT-PCR. (C) POF cells were transduced with HPV16 E6 wild-type, HPV16 E6 G130V, HPV16 E6 L110Q and pLXSN
retroviruses. At 24 h post-transduction, G418 (0.5 mg/ml)was added to the cells for 2 weeks. The plated cloneswere stainedwith crystal violet. A representative colony formation assay is
shown (left panel). Histograms represent the number of colonies quantiﬁed in each plate. Results are from three independent experiments (lower panel). (D) Growth proﬁles of POF cells
expressing the HPV16 E6 viral proteins and respective mutants. After selection, the growth of the different cell populations was monitored for more than 60 days.
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cells, but not in HPV16 E6 expressing cells. As for the E6mutants, their
abilities to prevent the binding of p150Sal2 on the p21WAF1 promoter
correlate with their efﬁciency in binding p150Sal2.
Together these data show that HPV16 E6 is able to prevent the
binding of p150Sal2 on the p21WAF1 promoter.
Discussion
We have previously observed that HPV16 is able to alter the
regulation of the restriction point in the G1 phase of the cell cycle by
down-regulation of p21WAF1 transcript by a mechanism that is
independent of p53 inactivation (Malanchi et al., 2004, 2002). Here,
we show that HPV16 E6 binds, stabilizes and inactivates the
transcription factor p150Sal2, which is implicated in the positive
regulation of the p21WAF1 promoter (Li et al., 2004). Mutation of
HPV16 E6 L110 greatly diminished p150Sal2 binding, stabilization and
inactivation. Importantly, the oncoprotein is able to prevent p150Sal2
association with p21WAF1 promoter, therefore inhibiting its transcrip-
tional functions.
It has been previously shown that p150Sal2 associates with another
protein from a DNA tumor virus, the large T antigen of mouse
polyomavirus (Li et al., 2001). This interaction was characterized in a
cellular assay, which allowed the identiﬁcation of p150Sal2 as a
negative regulator of viral replication (Li et al., 2001). Since viral
replication is dependent on the host DNA replication machinery and
G1-to-S progression, the inhibition of p150Sal2, and consequently
down-regulation of p21WAF1, represent a key event in the life cycle of
the virus. Therefore, based on the polyomavirus model, a similar
scenario could be envisaged for HPV16. The importance of the
neutralization of p21WAF1 for HPV16 life cycle is underlined by
the existence of several virus-mediated mechanisms to block the
functions of the CDK inhibitor. In fact, in addition to the ability of E6 torepress p21WAF1 transcription with p53-dependent and -independent
mechanisms, it has been shown that the other major HPV16
oncoprotein, E7, binds p21WAF1, preventing its interaction with
CDK2 and PCNA (Funk et al., 1997; Jones et al., 1997).
The existence of two distinct mechanisms of HPV16 E6 to repress
p21WAF1 transcription is not surprising. In fact, it is very likely that
p150Sal2 and p53 activate p21WAF1 transcription in different circum-
stances. In this scenario, E6 would be able to inhibit p21WAF1
transcription independently of the situation of the infected cell and
guaranteeing a constant and efﬁcient viral DNA replication. In addition,
it is very likely that p150Sal2 regulates the transcription of additional
cellular genes encoding proteins, which may play a negative role in the
HPV life cycle, and therefore needs to be neutralized.
Our data indicate that HPV16 E6 induces the accumulation of an
inactive form of p150Sal2. Interestingly, p150Sal2 levels were found to
be elevated in synovial sarcomas (Nielsen et al., 2003). In light of our
ﬁndings, we could speculate that the accumulation of p150Sal2 in this
pathological setting reﬂects the loss of its function.
In summary, we describe here a new mechanism for HPV16 E6
down-regulation of p21WAF1 transcription, independently of p53 in
which inactivation of p150Sal2 is required. It is likely that a similar
mechanism of inactivation of p21WAF1 expression occurs in other
cancers non- and virally induced.
Materials and methods
Cell culture
SaOS-2, SiHa, CaSki, HeLa, C33A, Phoenix and primary human oral
ﬁbroblast (POF) were grown in DMEM supplemented with 10% fetal
calf serum. Recombinant retroviruses, infections, doubling population
counting and colony assays were performed as previously described
(Caldeira et al., 2003; Mansour et al., 2007). Gene silencing of HPV16
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Fig. 4. HPV16 E6 induces accumulation of an inactive form of p150Sal2. (A) Immunoblotting of p21WAF1 and p150Sal2 levels in POFs transduced with empty retroviruses (pLXSN) or
wild type or mutated HPV16 E6 (left panel). Quantiﬁcation of p150Sal2 signal in indicated cells in three independent immunoblottings (right panel). (B) Immunoblotting of p21WAF1
and p150Sal2 levels in SaOS-2 cells transduced with empty retroviruses (pLXSN) or expressing HPV16 HA-E6. (C) Immunoblotting of p21WAF1 and p150Sal2 levels in C33A (HPV-
negative cervical cells line), CaSki, SiHa (HPV16-positive cell lines) and HeLa (HPV18-positives cells line). (D) p150Sal2 levels in CaSki cells transfected with HPV16 E6/E7 small
interfering RNAs. After preparation of total protein extracts p150Sal2 and β-tubulin protein levels were determined by immunoblotting using speciﬁc antibodies. (E) ChIP assay
determining the in vivo binding of p150Sal2 to the p21 promoter in SaOS-2 cells transduced with empty retroviruses (pLXSN) or expressing wild type or mutated HPV16 E6.
Chromatin was immunoprecipitated with the p150Sal2 antibody. A rabbit IgG isotype control was used as negative control. The sites BS1 and BS2 on the p21 promoter were ampliﬁed
by qPCR from transcription factor bound to DNA and the values obtained are referred as relative to the initial amount of DNA (input).
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following siRNA 5′ UUAAAUGACAGCUCAGAGG 3′.Plasmid constructs
The retroviral vectors pBabe-puro and pBabe-neo were described
previously (Morgenstern and Land, 1990), while the pLXSN construct
was obtained from Clontech (Palo Alto, CA, USA). The open reading
frames of HPV16 E6 wild-type and the twomutants G130V and L110Q
(kindly provided by Elliot Androphy, Indiana University, Indianapolis,
IN, USA) were ampliﬁed by PCR and cloned in pBabe-neo, pLXSN or
pGEX-4T1 expression vector (Amersham Biosciences, Piscataway, NJ,
USA) with or without the hemagglutinin (HA) tag sequence at the 5′
end. Full-length and serial deletions of p21WAF1 promoter in pJFACT1
were kindly provided by Bert Vogelstein (el-Deiry et al., 1993) and
Xiao-Fan Wang (Duke University Medical Center, Durham, NC, USA).
The p53 pRetroSuper construct was used as previously described(Accardi et al., 2006). The p150sal2 pcDNA was kindly provided by
Benjamin Thomas (Harvard Medical School, Boston, MA, USA). The
p150sal2-Flag was cloned in pcDNA-Flag between HpaI and BamH1.Determination of p21WAF1 promoter activity
POF were transfected with 1 μg or 3.5 μg of the p21WAF1 luciferase
or chloramphenicol acetyl transferase (CAT) reporter plasmids
respectively, HPV16 E6 plasmid at different concentrations. Luciferase
activity was measured with a dual luciferase assay kit (Promega,
Madison, WI, USA) according to the manufacturer's instructions using
the luminometer (Optocomp I; MGM instrument, Hamden, CT, USA).
Renilla luciferase activity or beta-galactosidase activity was used to
normalize transfection efﬁciency. CAT assays were performed with
40 μg of protein incubated with 2.5 μl acetyl-CoA and 1.5 μl [14C]
chloramphenicol (Amersham, Piscataway, NJ, USA). Following
extraction with ethyl acetate, samples were analyzed by thin layer
448 P. Parroche et al. / Virology 417 (2011) 443–448chromatography and visualized by autoradiography. Quantiﬁcation
was performed by excising the products and liquid scintillation
counting.
Biochemical analyses
Preparation of total protein cellular extracts and immunoblotting
were performed as previously described (Accardi et al., 2006).
Immunoblottings were performed with following antibodies: anti-
p150Sal2 antibody (Benjamin Thomas, Harvard Medical School,
Boston, MA, USA and Santa Cruz Biotechnology, Santa Cruz, USA),
anti-ß-tubulin (Sigma-Aldrich, St Louis, MI, USA), anti-p21WAF1 (Cell
Signaling, Danvers, MA, USA), anti-β-actin (Sigma-Aldrich, St Louis,
MI, USA), anti-GST (generous gift from Georges Mosialos, Institute of
Immunology, Biomedical Sciences Research Center Al. Fleming, Vari,
Greece), anti-Flag M2 (Sigma-Aldrich, St Louis, MI, USA), and anti-HA
(Roche, Mannheim, Germany). All densitometry analyses were
performed using the BIORAD phosphor-imager.
For the immunoprecipitation, cleared lysates were incubated
overnight at 4°C with anti-Flag or anti-HA. After addition of protein
A/G plus agarose (Santa Cruz Biotechnology), immunoprecipitates
were collected and subjected to a 15% or a 10% SDS-PAGE and
transferred to a membrane.
The GST pull down assays were performed as previously described
(Caldeira et al., 2003).
ChIP assay was performed using previously described protocol
(Zannetti et al., 2010) using the p150Sal2 provided by Santa Cruz
Biotechnology. The qPCR was carried out with a set of two primers
amplifying the twopredicted regionsof thep150Sal2 bindingsite (p150Sal2
BS) on the human p21WAF1 promoter (Table 1, Supplementary material).
Quantitative RT-PCR
Total RNA extraction and cDNA synthesis were performed as
previously described (Hasan et al., 2007). Real-time PCR was
performed by using the LightCycler® FastStart DNA MasterPLUS SYBR
Green I kit (Roche, Mannheim, Germany) in a LightCycler ﬂuores-
cence temperature cycler according to the manufacturer's instruc-
tions. Primers used for RT-PCR and real-time PCR are listed in Table 1
(Supplementary material).
Supplementarymaterials related to this article can be found online
at doi:10.1016/j.virol.2011.05.016.
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